5.49 +0.03 (0.55%)
After hours: 7:56PM EDT
|Bid||5.47 x 2900|
|Ask||5.49 x 1800|
|Day's Range||5.44 - 5.58|
|52 Week Range||1.74 - 6.99|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.75|
Now that the biotechnology sector is well on its way to bouncing back after bottoming in May 2018, investors may feel like they missed out. The fears that previously plagued biotech stocks are no longer as big a threat. The government is no longer putting companies hiking drug price in their cross-hairs, at least not for now. This favorable environment should help biotech firms carry out their plans for the rest of the year.
HENDERSON, NV / ACCESSWIRE / September 19, 2018 / The stem cell market has been very active recently, several stocks have been making deals and major breakthroughs. One stem cell play the market seems ...
On Thursday, President Donald Trump instructed aides to carry on with $200 billion tariffs against Chinese goods. The Nasdaq Composite Index dropped 0.05 percent to close at 8,010.04, gained 1.4 percent for the week.
Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...
HENDERSON, NV / ACCESSWIRE / September 14, 2018 / Last week, Sangamo Therapeutics became the first company to edit a patient's DNA inside the body, usually the process is done outside the body. This is ...
Geron (GERN) has been one of the best-performing biotechnology companies in the last month, rising 67.1% since August 10. On November 13, 2014, Geron announced a collaboration with Janssen Biotech, a subsidiary of Johnson & Johnson, for the development and commercialization of imetelstat, its investigational telomerase inhibitor across various hematologic malignancies and especially in myelofibrosis (or MF).
The big focus as of late has been on immunotherapies and advanced regenerative therapies, which has helped drive innovation and new growth within the space. Specifically, cancer immunotherapy is expecting strong growth based on the increased number of deaths as a result of cancer. New treatments beyond basic chemotherapy are being developed and higher demand for things like immunotherapy continue to push the need for companies to adapt.
HENDERSON, NV / ACCESSWIRE / September 6, 2018 / Biotech stocks have been making investors major profits for years. Recently, the stem cell market has started to heat up again. One stock leading that push ...
Clinical trial results on the way could change the way investors feel about these biotech stocks before the leaves start falling.
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in Janssen sponsored studies.
The biotech sector notched strong gains last week, capitalizing on the positive overall market sentiment, set in motion by the trade deal between the U.S. and Mexico. Here are a few catalysts that could ...
HENDERSON, NV / ACCESSWIRE / August 30, 2018 / Small-Cap Biotech and Cannabis stocks have been receiving a lot of attention from the investment community as of late. With conference season right around ...
On August 24, Geron (GERN) stock rose ~28.78% to $5.19 from its prior day’s close of $4.03. On August 24, Geron stock was ~29% below its 52-week high of $6.68 on March 22. On August 24, Johnson & Johnson (JNJ) posted a job opening that mentioned imetelstat.
Last Friday, Geron's shares spiked on a job posting by its partner Johnson & Johnson that seems to indicate that a key decision on a drug is near.
CORAL GABLES, FL / ACCESSWIRE / August 24, 2018 / The Medical sector is one of the sectors to have recorded consistent earnings growth over the last few quarters. GT Biopharma (GTBP) saw its shares climb to highs of $2.10 on Friday morning. The company announced today that it has appointed David Cardino, CPA, MBA as Vice President of Finance.